open access

Vol 14, No 2 (2011)
Original articles
Published online: 2012-01-04
Submitted: 2012-01-23
Get Citation

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefańska, Monika Tomaszuk, Wioletta Lenda-Tracz, Renata Mikołajczak, Dariusz Pawlak, Robert Chrzan, Aleksandra Gilis-Januszewska, Elwira Przybylik-Mazurek, Alicja Hubalewska-Dydejczyk
Nucl. Med. Rev 2011;14(2):73-78.

open access

Vol 14, No 2 (2011)
Original articles
Published online: 2012-01-04
Submitted: 2012-01-23

Abstract

BACKGROUND: The aim of the study was to assess the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with non-functioning neuroendocrine pancreatic tumours (NFPNTs) and to compare survival rates in patients with NFPNTs and in patients with other neuroendocrine tumours (NETs) treated using radiolabelled somatostatin analogue in our Department. We would like to analyze factors potentially determining the effectiveness of the therapy and also to assess the myelo- and nephrotoxicity.
MATERIAL AND METHODS: Fourteen patients with disseminated disease and/or inoperable NFPNT were qualified to PRRT based on positive SRS (somatostatin receptor scintigraphy). There were 5 men and 9 women, with Karnofsky’s index > 70%.
RESULTS: In the whole group of patients, partial response was observed in 21.4%, stabilization of the disease in 42.9%, and progression of the disease in 35.7% of patients. Mean observation time was 19 ± 13 months, mean time to progression was 12 ± 9 months, and mean time to death was 16 ± 9 months. Six patients died — four of them due to progression of the disease, two due to myocardial infarction. After PRRT we did not observe clinically significant haemotoxicity and/or nephrotoxicity.
CONCLUSIONS: 1. Peptide receptor radionuclide therapy may be a safe and effective treatment option in patients with NFPNTs, leading to stabilization or regression of the disease in the majority of patients. 2. There is no statistically significant difference in survival rate between patients with NFPNTs and NETs of other localization treated with PRRT.
Nuclear Med Rev 2011; 14, 2: 73–78

Abstract

BACKGROUND: The aim of the study was to assess the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with non-functioning neuroendocrine pancreatic tumours (NFPNTs) and to compare survival rates in patients with NFPNTs and in patients with other neuroendocrine tumours (NETs) treated using radiolabelled somatostatin analogue in our Department. We would like to analyze factors potentially determining the effectiveness of the therapy and also to assess the myelo- and nephrotoxicity.
MATERIAL AND METHODS: Fourteen patients with disseminated disease and/or inoperable NFPNT were qualified to PRRT based on positive SRS (somatostatin receptor scintigraphy). There were 5 men and 9 women, with Karnofsky’s index > 70%.
RESULTS: In the whole group of patients, partial response was observed in 21.4%, stabilization of the disease in 42.9%, and progression of the disease in 35.7% of patients. Mean observation time was 19 ± 13 months, mean time to progression was 12 ± 9 months, and mean time to death was 16 ± 9 months. Six patients died — four of them due to progression of the disease, two due to myocardial infarction. After PRRT we did not observe clinically significant haemotoxicity and/or nephrotoxicity.
CONCLUSIONS: 1. Peptide receptor radionuclide therapy may be a safe and effective treatment option in patients with NFPNTs, leading to stabilization or regression of the disease in the majority of patients. 2. There is no statistically significant difference in survival rate between patients with NFPNTs and NETs of other localization treated with PRRT.
Nuclear Med Rev 2011; 14, 2: 73–78
Get Citation

Keywords

non-functioning neuroendocrine pancreatic tumours; peptide receptor radionuclide therapy; radiolabelled somatostatin analogues

About this article
Title

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Journal

Nuclear Medicine Review

Issue

Vol 14, No 2 (2011)

Pages

73-78

Published online

2012-01-04

Bibliographic record

Nucl. Med. Rev 2011;14(2):73-78.

Keywords

non-functioning neuroendocrine pancreatic tumours
peptide receptor radionuclide therapy
radiolabelled somatostatin analogues

Authors

Anna Sowa-Staszczak
Dorota Pach
Agnieszka Stefańska
Monika Tomaszuk
Wioletta Lenda-Tracz
Renata Mikołajczak
Dariusz Pawlak
Robert Chrzan
Aleksandra Gilis-Januszewska
Elwira Przybylik-Mazurek
Alicja Hubalewska-Dydejczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl